As the COVID-19 pandemic progresses and continues to affect everyday life around the world, the path that lies ahead for the MedTech industry and the search for effective therapeutics and vaccines remains hard to predict.
The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.
Based on prelim Q220 MedTech Company results, SVB Leerink expects May/June COVID recovery to exceed expectations noting elective procedure shutdowns are regionalized and halts are not expected to be as bad or prolonged as in March/April. SVBLeerink Medical Supplies and Devices
With 4 of the leading vaccine candidates expected to enter Phase 3 studies in July (Sinovac, Moderna, BioNTech/PFE, CanSino), Phase 2 data could be reported in summer/fall 2020. If +, WFS says it could be a catalyst for some medtech sectors in recovery of elective procedures.
A survey assessing public perceptions towards resuming elective surg found out of 722 people 61% were concerned w/ contracting COVID-19 during surg. Overall, 57% would have surgery at a hospital vs outpatient and 27% would undergo surg in the first mo of reopening. J Arthroplasty
The European Commission published a document about the preparedness of health systems in Europe for future COVID-19 outbreaks. Topics comprise testing, contact tracing, surveillance, accessibility of medical devices and capacity measures.